Sidley represented Morgan Stanley and Leerink Partners, as representatives of the underwriters, in connection with Pharvaris N.V.’s (“Pharvaris”) US$201.2 million upsized public offering of ordinary shares and pre-funded warrants and full exercise of the underwriters’ option to purchase additional shares. Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema.
The deal team was led by Frank Rahmani, Sam Gandhi, and Kostian Ciko, and included Istvan Hajdu and Kunchok Yaklha (Capital Markets), Emily Marden and Jaclyn Fonteyne (Food, Drug and Medical Device), Alison Lehner (Emerging Companies and Venture Capital), and Rachel Kleinberg and Jonathan Westreich (Tax).
